LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | A443654 | 0.37 | uM | LJP6 | 72 | hr | 1657 | 1495 | 5505 | 0.2716 | -0.0422 |
BT-20 | OSI-027 | 0.37 | uM | LJP6 | 72 | hr | 1657 | 3446 | 5505 | 0.6260 | 0.4649 |
BT-20 | XMD11-85h | 0.37 | uM | LJP6 | 72 | hr | 1657 | 5229 | 5505 | 0.9498 | 0.9281 |
BT-20 | HG-6-64-01 | 0.37 | uM | LJP6 | 72 | hr | 1657 | 4625 | 5505 | 0.8401 | 0.7712 |
BT-20 | WH-4-025 | 0.37 | uM | LJP5 | 72 | hr | 1657 | 3593 | 5505 | 0.6527 | 0.5031 |
BT-20 | WZ-4-145 | 0.37 | uM | LJP6 | 72 | hr | 1657 | 4652 | 5505 | 0.8451 | 0.7783 |
BT-20 | XMD16-144 | 0.37 | uM | LJP5 | 72 | hr | 1657 | 2144 | 5505 | 0.3894 | 0.1264 |
BT-20 | Brivanib | 0.37 | uM | LJP5 | 72 | hr | 1657 | 5313 | 5505 | 0.9651 | 0.9501 |
BT-20 | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 1657 | 3669 | 5505 | 0.6665 | 0.5229 |
BT-20 | BX-912 | 0.37 | uM | LJP5 | 72 | hr | 1657 | 5456 | 5505 | 0.9910 | 0.9872 |
BT-20 | Canertinib | 0.37 | uM | LJP6 | 72 | hr | 1657 | 4568 | 5505 | 0.8298 | 0.7565 |
BT-20 | Celastrol | 0.37 | uM | LJP6 | 72 | hr | 1657 | 4608 | 5505 | 0.8370 | 0.7667 |
BT-20 | CGP60474 | 0.37 | uM | LJP5 | 72 | hr | 1657 | 1541 | 5505 | 0.2800 | -0.0303 |
BT-20 | CGP60474 | 0.37 | uM | LJP6 | 72 | hr | 1657 | 1032 | 5505 | 0.1876 | -0.1624 |
BT-20 | CHIR-99021 | 0.37 | uM | LJP6 | 72 | hr | 1657 | 5511 | 5505 | 1.0010 | 1.0015 |
BT-20 | CP724714 | 0.37 | uM | LJP5 | 72 | hr | 1657 | 4890 | 5505 | 0.8882 | 0.8401 |
BT-20 | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 1657 | 5847 | 5505 | 1.0620 | 1.0887 |
BT-20 | Crizotinib | 0.37 | uM | LJP5 | 72 | hr | 1657 | 4808 | 5505 | 0.8733 | 0.8187 |
BT-20 | Momelotinib | 0.37 | uM | LJP5 | 72 | hr | 1657 | 4385 | 5505 | 0.7965 | 0.7089 |
BT-20 | Dasatinib | 0.37 | uM | LJP5 | 72 | hr | 1657 | 1894 | 5505 | 0.3440 | 0.0614 |
BT-20 | Dasatinib | 0.37 | uM | LJP6 | 72 | hr | 1657 | 1678 | 5505 | 0.3049 | 0.0054 |
BT-20 | Dovitinib | 0.37 | uM | LJP5 | 72 | hr | 1657 | 3165 | 5505 | 0.5749 | 0.3918 |
BT-20 | Enzastaurin | 0.37 | uM | LJP5 | 72 | hr | 1657 | 6128 | 5505 | 1.1130 | 1.1617 |
BT-20 | Erlotinib | 0.37 | uM | LJP5 | 72 | hr | 1657 | 5023 | 5505 | 0.9123 | 0.8746 |
BT-20 | Foretinib | 0.37 | uM | LJP5 | 72 | hr | 1657 | 3174 | 5505 | 0.5766 | 0.3942 |